Should Household Air Quality Monitoring Be Considered in Selected Asthma & COPD Patients?

Rubèn González-Colom[1] PhD; Alba Gómez-López[1] MSc, RN; Alicia Aguado[2] MSc; Néstor Soler[3] PhD, MD; Núria Sánchez-Ruano[4], PhD, MD; Marta Sorribes[5], MD; Jaume Benavent[4], PhD, MD; Antoni Sisó-Almirall[4], PhD, MD; Antonio Montilla-Ibarra[5], MD; Maria Figols[6] MSc; Alberto Rodríguez[7], PhD; Emili Vela[8,9], MSc; Jordi Piera-Jiménez[8,9]; PhD; Ramon Farré[10], PhD; Josep Roca[1], PhD, MD; Isaac Cano[1,10], PhD; Jose Fermoso[2], MSc; Ebymar Arismendi[3,11], PhD, MD.

1. Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS). Barcelona, Spain.
2. CARTIF Technology Center. Valladolid, Spain
3. Pulmonology Department, Hospital Clinic de Barcelona. Barcelona, Spain
4. Consorci d'Atenció Primaria de Barcelona-Esquerra (CAPSBE), Barcelona, Spain.
5. CAP Numancia, Institut Catala de la Salut (ICS). Barcelona, Spain.
6. inBiot. Pamplona, Spain
7. Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT). Madrid, Spain
8. Catalan Health Service. Barcelona, Spain
9. Digitalization for the Sustainability of the Healthcare System (DS3) – IDIBELL. Barcelona, Spain.
10. Universitat de Barcelona. Barcelona, Spain.
11. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III. Madrid, Spain.

Corresponding author: Rubèn González-Colom

C/ Roselló, 149, 08036, Barcelona, Spain

+34 93 227 57 07

rgonzalezc@recerca.clinic.cat

Abstract

Background: Indoor air quality (IAQ) is an actionable determinant of respiratory health. Low-cost sensors (LCS) could enable scalable, patient-centred assessments, but real-world clinical utility is uncertain.

Objective: Evaluate the feasibility and usability of home IAQ monitoring with LCS and synthesise lessons directly relevant to clinical management.

Methods: We conducted an ambispective cohort study involving 205 adults with COPD, bronchiectasis, or asthma. Household IAQ was profiled prospectively over two months using LCS that logged CO_2, $PM_{2.5}$ and formaldehyde every 10 minutes. For each pollutant, dwellings were classified as Good, Moderate or Unhealthy according to the Global Open Air Quality Standards thresholds. Clinical surveillane were conducted over the preceding 12 months, with pulmonary exacerbations requiring hospitalization as the primary endpoint and all-cause emergency department visits as an exploratory endpoint.

Results: More than half of homes (92; 51.7%) had at least one pollutant in an at-risk category. The burden was driven by $PM_{2.5}$: 40.1% of dwellings were classified as at risk (32.8% Moderate; 7.3% Unhealthy). Formaldehyde exceeded the low-risk threshold in 22 homes (12.4%). The prevalence of smokers rose steeply across $PM_{2.5}$ categories ($p<0.001$). Despite this high prevalence of at-risk IAQ, the distribution of IAQ categories was comparable between patients with and without hospitalised exacerbations; a similar pattern was observed for all-cause ED visits.

Conclusion: 1) LCS show stable, near-linear performance, enabling reliable detection of IAQ trends. They are well-suited for IAQ risk screening, but continuous long-term monitoring is not cost-efficient. 2) Impaired IAQ is a prevalent phenomenon, $PM_{2.5}$ driven and strongly linked to indoor smoking. 3) IAQ risk categories did not associate directly with unplanned hospitalisations, instead, risk was driven by multimorbidity burden, pulmonary disease severity, and history of previous events.

Registration: NCT06421402.

Keywords: Asthma; COPD; Household IAQ monitoring; Low-cost sensors; Multimorbidity; Unplanned hospitalizations.

Introduction

Exposure to air pollution is considered the most important environmental health risk factor with significant deleterious impacts on physiological developments during early life and accelerated functional decline in the elderly[1]. There is also robust evidence of both acute and sustained adverse effects of air pollution on several organs and systems, with respiratory disorders being one of the primary concerns[2–6]. Specifically, the effects of exposure to particulate matter (PM), as well as oxidants like nitrogen oxides (NOx) and ozone (O_3), have been extensively demonstrated[7]. The exposure to formaldehyde (CH_2O) is also associated with asthma diagnosis and exacerbations[8,9]. Furthermore, there is growing attention on the negative impact of other airborne pollutants, such as volatile organic compounds (VOCs)[10] .

Due to the magnitude of the burden of air pollution on human health, international agencies[11–14] are actively deploying public health policy actions. In this context, research on indoor air quality (IAQ) is raising interest due to unknowns on the sources of indoor pollution[15,16], the interactions between IAQ and outdoor air quality, and most importantly, the lack of available information to generate appropriate regulations and health policies on IAQ, as reported in two recent official statements of the American Thoracic Society (ATS)[17,18]. Likewise, the European Union launched the IDEAL Cluster in 2022[19], an ambitious research and innovation program encompassing seven consortia working on coordinated action plans to set IAQ standards. One of the relevant areas of action of the IDEAL cluster is to explore the potential of low-cost sensors (LCS) for IAQ monitoring in health-related applications. LCS are gaining traction due to their potential for remote continuous IAQ monitoring of different pollutants, affordability, applicability, and potential for widespread deployment in different scenarios[20–22].The harmful effects of IAQ on respiratory health have been consistently proven in patients with chronic obstructive pulmonary disease (COPD)[5,23–25] showing significant associations between indoor pollutants and symptoms, functional capacity and risk of exacerbations.

Interestingly, the CLEAN AIR[23] study showed potential health benefits of portable particulate air cleaners. A recent report highlighted that the harmful effects of PM pollution on cardiovascular health in patients with COPD can be mitigated by reducing exposure[4], suggesting a potential role for household IAQ monitoring in high-risk patients. As stated, LCS might open a window of opportunity to enhance the management of selected patients with chronic obstructive respiratory diseases. LCS are useful for detecting risk environments due to poor IAQ, helping users to avoid overexposure to indoor pollutants. It is acknowledged, however, that there are uncertainties regarding the quality of LCS measurements, and their potential for applicability in healthcare[20–22].

Accordingly, our primary objective was to evaluate the feasibility and usability of home IAQ monitoring with LCS and to synthesise lessons with direct relevance for clinical management[26–28]. To do this, we used an ambispective design combining: (i) a prospective characterisation of household IAQ in high-risk adults with COPD, bronchiectasis or asthma using continuous LCS measurements of CO_2, formaldehyde, and $PM_{2.5}$; and (ii) a retrospective assessment of associations between dwelling-level IAQ status and severe acute events, specifically unplanned hospitalisations with a principal respiratory diagnosis and all-cause emergency room visits.

The research was developed within the framework of the K-HEALTHinAIR project[29], particularly addressing the assessment of a preventive intervention aiming at improving community-based management of exacerbations in high-risk chronic respiratory patients to reduce unplanned hospitalizations. It consisted of a two-year follow-up, 2024 and 2025, of 205 chronic respiratory patients, as reported in detail in [28].

Materials and Method

Study cohort

Between October 2023 and March 2025, we enrolled 205 patients with COPD or bronchiectasis or asthma from two complementary settings. Most participants (n = 152; 77%) were recruited through four primary care centres in the Barcelona-Esquerra Integrated Care Area (AISBE)[30] , each serving approximately 20,000 residents. These patients were identified in the Catalan Health Surveillance System (CHSS)[31] with a diagnosis ICD-10-CM[32] J44 (COPD), J45 (asthma) and J47 (bronchiectasis) and classified as high-risk due to disease severity and/or multimorbidity, defined as an Adjusted Morbidity Groups (AMG)[33–35] score at or above the 80th percentile of the regional risk pyramid. The remaining patients (n=53; 23%), all with stage 5 or 6 asthma[36,37], were enrolled at the Severe Asthma Unit at Hospital Clinic de Barcelona.

Eligibility criteria, recruitment procedures, and monitoring protocols are detailed in the published study protocol[28]. Throughout the study, clinical management followed international recommendations for COPD[38,39] , bronchiectasis[40], asthma[36,37] management.

Study design and IAQ evaluation

Conducted and reported in accordance with STROBE[41] guidelines, this ambispective cohort study of high-risk adults with COPD or asthma combined two months of prospective in-home IAQ characterisation with one year of retrospective surveillance for acute events (**Figure 1**).

Figure 1: Study timeline and design. *(A) Ambispective cohort. Prospective in-home IAQ monitoring (purple) was conducted from 1 April to 31 May 2025. Retrospective healthcare surveillance (light blue; 1 April 2024–31 March 2025) captured acute events: severe pulmonary exacerbations leading to unplanned hospital admission with a principal respiratory diagnosis (ICD-10-CM J00–J99; red stars) and all-cause emergency department visits (blue stars). (B) Long-term exposure thresholds from the Global Open Air Quality Standards (GO-AQS) used to classify household IAQ as Good, Moderate, or Unhealthy for CO_2, formaldehyde, and $PM_{2.5}$.*

Prospective in-home IAQ monitoring (1 Apr 2025 – 31 May 2025).

To characterise household IAQ burden, patient dwellings were equipped with MICA-IBIOT's[42] LCS to continuously record key IAQ parameters every 10 minutes, including temperature, relative humidity, CO_2, PM1, PM2.5, PM10, formaldehyde and total VOCs concentrations (**Figure 1A**). The **Supplementary Material** contents detailed information on the manufacturer specifications of the used IAQ sensors and details the validation work conducted within the K-HEALTHinAIR project[29], comprising chamber tests and in-field comparisons, to assess accuracy, linearity, inter-sensor agreement, and drift. In short, the sensor performance for PM and formaldehyde met predefined quality criteria and was adequate for the study objectives; by contrast, total VOC measurements failed quality thresholds and were excluded from analysis.

To assess indoor pollution levels and stratify homes according to their IAQ quality for different parameters, we applied the reference framework outlined in the Global Open Air Quality Standards (GO AQS) white paper[43]. Subsequently, dwellings were classified using the GO-AQS framework adapted for long-term exposure assessment of the key pollutants monitored: CO_2, formaldehyde, and PM2.5. The concentration of each pollutant in the patient's home were classified in three categories: i) Good, ii) Moderate, or iii) Unhealthy ranges, according to the thresholds described in **Figure 1B** . Homes were classified based on their all-time average pollutant concentrations and stratified

according to their IAQ status for each parameter. Additionally, the relative frequency of time spent in each risk category was calculated to provide a more detailed analysis of exposure patterns and variability[44,45].

Retrospective clinical surveillance (1 Apr 2024 – 31 Mar 2025).

To examine the associations between household indoor pollution and severe health events, we retrieved from the CHSS the registries of acute care events over the preceding year (**Figure 1A**). The primary outcome was severe pulmonary exacerbations requiring unplanned hospital admission with a principal respiratory diagnosis (ICD-10-CM J00–J99). Planned admissions and non-respiratory urgent admissions were excluded. All-cause emergency department visits were captured as an exploratory outcome, since visit cause was not recorded in the CHSS. For IAQ analyses, we excluded the cases with less than 30 complete monitoring days and those patients who discontinued follow-up.

Statistical analysis

Numeric variables are described as mean and standard deviation (SD) or median and interquartile range (IQR, Q1–Q3), depending on their distribution. Categorical variables are summarized as counts and percentages; n (%). The comparison of numerical outcomes between patients with respiratory disease exacerbations requiring hospital admission and those who did not was conducted using Student's t-test for normally distributed variables or the Mann-Whitney U test for non-normally distributed variables. The frequency distributions of categorical factors were compared using Fisher's exact test. A p-value of <0.05 was considered statistically significant. All statistical analyses were performed using R, version 4.1.1[46].

Ethics approval and consent to participate

The Ethical Committee for Human Research at the Hospital Clínic de Barcelona approved the core study protocol for K-Health in Air on June 29, 2023 (HCB/2023/0126). The study design aligns with the data minimisation principles, ensuring that only the data strictly necessary for the research are collected and utilised. It will be carried out per the Declaration of Helsinki and adheres to the protocol and applicable legal requirements, including the Biomedical Research Act 14/2007 of July 3.

All participants in the study had to sign an informed consent form before undergoing any procedures. They were informed that they could withdraw their consent at any point, without affecting their

relationship with their physician or compromising their medical treatment. The study has been registered at ClinicalTrials.gov (Identifier: NCT06421402).

Results

Characteristics of the study cohort

Within the K-HEALTHinAIR cohort, 205 participants were enrolled between October 2023 and March 2025. However, during the prospective IAQ monitoring window reported in this manuscript, 27 participants (13.2%) were not evaluable, yielding a final analytic sample of 178 patients (86.8%). Of these, 130 (73.0%) were from the community program and 48 (27.0%) from the Severe Asthma Unit. The exclusion reasons are the following: 19 (9.3%) dropped out, 3 (1.5%) died, and 5 (2.4%) were excluded because of IAQ sensor malfunction or insufficient data.

Table 1 summarises baseline characteristics of the study cohort (n=178), stratified by patients with one or more unplanned hospitalisation due to a severe pulmonary exacerbation (n=50; 28.1%) versus those without such events (n=128; 71.9%). Over the one-year retrospective surveillance, 69/178 (38.8%) patients accounted for 113 hospitalisations: 31/113 (27.4%) were planned and 82/113 (72.6%) were urgent. Among urgent admissions, 68/82 (82.9%) were due to respiratory exacerbations, corresponding to 50/178 (28.1%) patients; the remaining 14/82 (17.1%) urgent admissions were for non-respiratory causes.

TABLE 1 – Main features of the study group: Comparisons between patients showing unplanned hospitalizations during the study period (n=50) and all the other patients (n=128)

Variable	All other patients (n=128)	Patients with unplanned hospitalizations (n=50)	p-value
Age, Gender and Smoking habit			
Age; mean (SD)	66.96 (12.17)	68.04 (12.01)	.596
Male; n (%)	50 (39.06)	25 (50)	.237
Female; n (%)	78 (60.94)	25 (50)	
Current Smokers; n (%)	16 (12.5)	9 (18)	0.304
Former Smokers; n (%)	73 (57.03)	31 (62)	
Never Smokers; n (%)	39 (30.47)	10 (20)	
Main Respiratory Diagnosis, Co-morbidities and Forced Spirometry			
COPD; n (%)	60 (46.88)	33 (66)	.166
Asthma, n (%)	11 (8.59)	3 (6)	
Bronchiectasis, n (%)	19 (14.84)	4 (8)	
Severe asthma; n (%)	38 (29.69)	10 (20)	

AMG score; mean (SD)	71.09 (42.48)	97.93 (50.96)	**<.001**
AMG risk group - Very high risk; n (%)	9 (7.03)	11 (22)	.007
AMG risk group – High risk; n (%)	37 (28.91)	19 (38)	
AMG risk group – Moderate risk; n (%)	54 (42.19)	15 (30)	
AMG risk group – Low risk; n (%)	25 (19.53)	3 (6)	
AMG risk group – Very low risk; n (%)	3 (2.34)	1 (2)	
FVC; z-score, mean (SD)	-1.09 (1.28)	-1.46 (1.34)	0.121
FEV1; z-score, mean (SD)	-1.85 (1.37)	-2.51 (1.42)	**0.009**
FEV1/FVC; mean (SD)	62.63 (13.94)	53.28 (17.16)	**<.001**
Utilization of healthcare resources during the 12 months before retrospective clinical surveillance			
All-cause hospitalizations; n (%)	32 (25.00)	31 (62.00)	**<.001**
Unplanned hospitalizations; n (%)	18 (14.06)	29 (58.00)	**<.001**
Total healthcare expenditure per patient in €; median (Q1-Q3)	4581 (2,455 – 9,727)	8,541 (5,157 – 14,057)	**<.001**

AMG score: Adjusted Morbidity Groups score, indicating co-morbidities and complexity; COPD: Chronic Obstructive Pulmonary Disease; FVC: Forced Vital Capacity; FEV1: Forced Expiratory Volume in 1 second; FEV1/FVC: Ratio of FEV1 to FVC; Total healthcare expenditure corresponds to total expenditure per year across all healthcare tiers.

As displayed in **Table 1**, the patients who experienced at least one unplanned respiratory hospitalisation due to a pulmonary exacerbation along the previous year before the IAQ assessment (n=50) had a substantially higher multimorbidity burden and more severe airflow limitation than those without events (n=128). The mean AMG score was higher in the hospitalised group (p<.001), with an over-representation in the very-high-risk band (p=.007). Prior healthcare use in the preceding year was markedly higher among patients with subsequent unplanned admissions: All-cause hospitalisations (p<.001), unplanned hospitalisation (p<.001), and greater total healthcare expenditure (p<.001). Spirometry showed worse obstruction among hospitalised patients: lower FEV_1 z-score (p=.009) and lower FEV_1/FVC (p<.001), while FVC z-score differences were not significant. Age, sex distribution, and smoking status were similar across groups. The distribution of primary respiratory diagnoses was broadly comparable. Collectively, severe pulmonary exacerbations manifested in individuals with greater clinical complexity, expressed as comorbidity burden and previous usage of healthcare resources, and worse airflow obstruction rather than differences in age, sex, smoking habits, or diagnostic labels.

Household IAQ monitoring

Table 2 summarizes the GO-AQS long-term thresholds for CO_2, formaldehyde, and $PM_{2.5}$, defining Low, Moderate, and Unhealthy exposure categories. It further reports, for each pollutant, the distribution of homes by category based on dwelling-level mean concentrations, and among these, the number of homes with any smoker present, and finally the overall monitoring time spent in each risk band. Among the 178 monitored homes, 92 (51.7%) exhibited at-risk pollution levels (moderate or unhealthy) for at least one monitored contaminant highlighting the prevalence of poor IAQ. CO_2 levels were generally within safe limits, with 163 (91.6%) homes classified as low risk and 14 (7.9%) falling into the moderate category. Only 1 (0.5%) home exceeded the unhealthy threshold for CO_2. In contrast, formaldehyde pollution was more widespread, with 22 homes (12.4%) exceeding the low-risk threshold, 21 in the moderate category (11.9%) and 1 (0.5%) classified as unhealthy. $PM_{2.5}$ exposure was the most concerning, as 71 homes (40.1%) showed at-risk levels, with 58 in the moderate category (32.8%) and 13 in the unhealthy category (7.3%).

TABLE 2 – Results of household indoor air quality monitoring grouped by each of the three risk categories defined by the Global Open Air Quality Standards (GO AQS)[40]

Parameter	Low risk	Moderate risk	Unhealthy risk
CO$_2$			
Recommended Thresholds, ppm	**400-850**	**851-1400**	**1401-5000**
Homes in category; n(%)	163 (91.6%)	14 (7.9%)	1 (0.5%)
Homes with any smoker; n(%)	45 (27.6%)	2 (14.3%)	0 (0%)
Monitoring time in category, hours; n(%)	200,929 (84.8%)	29,955 (12.7%)	5,870 (2.5%)
PM$_{2.5}$			
Recommended Thresholds, µg/m3	**0-8**	**9-35**	**36-400**
Homes in category; n(%)	106 (59.9%)	58 (32.8%)	13 (7.3%)
Homes with any smoker; n(%)	10 (9.4%)	26 (44.8%)	11 (84.6%)
Monitoring time in category, hours; n(%)	180,734 (76.6%)	36,699 (15.6%)	18,499 (7.8%)
Formaldehyde			
Recommended Thresholds, µg/m3	**0-50**	**51-120**	**121-500**
Homes in category; n(%)	155 (87.6%)	21 (11.9%)	1 (0.5%)
Homes with any smoker; n(%)	45 (29.0%)	2 (9.5%)	0 (%)
Monitoring time in category, hours; n(%)	196,862 (83.4%)	37,410 (15.9%)	1,665 (0.7%)
GO AQS Recommendations			
	Ideal air quality -	Reduce sources of pollution. Cut back	Avoid all physical activities (wear

	Enjoy activities	or reschedule strenuous activities indoors. Ventilate if possible.	N95/FFP3 masks and use personal or central air filtration systems in case of particle pollution or high CO_2 levels)

As depicted in **Table 2**, smokers in dwellings varied across the different air quality risk categories, showing a clear association with $PM_{2.5}$ pollution levels, whereas smoker prevalence showed no increasing gradient across CO_2 or formaldehyde categories. In homes classified as low risk for $PM_{2.5}$, only 10 (9.4%) had smokers, whereas this proportion increased to 26 (44.8%) in moderate-risk homes and reached 11 (84.6%) in unhealthy environments. This strong association (p <.001) suggests that smoking is a major contributor to fine particulate pollution indoors.

Analysing the time spent in each risk category suggests distinct emission patterns. $PM_{2.5}$ exposure showed a different pattern, with 59.9% of homes classified as low risk, but spending 76.6% of the time in this category (**Table 2**). This suggests acute pollution peaks driving $PM_{2.5}$ exposure. **Figure 1 – Panel A** shows a representative 24-h $PM_{2.5}$ time series from an at-risk dwelling, illustrating typical indoor exposure dynamics. $PM_{2.5}$ pollution is manifested as pronounced diurnal peaks, exceeding "Moderate" or "Unhealthy" thresholds for short periods, potentially coinciding with activities such as cooking, cleaning (particularly sweeping or dusting, which resuspends particles), and, most prominently, tobacco use indoors. Other episodic sources included the burning of incense or candles. Nighttime concentrations tended to decrease sharply, consistent with particle sedimentation in the absence of human activity.

Figure 1 – Panel B presents a 24-h monitoring segment from a dwelling representative of high formaldehyde contamination. Conversely, Formaldehyde exposure appears to be continuous, with 87.6% of homes classified as low risk, while spending only 83.4% of the monitored time in this category (**Table 2**). This behaviour reflects passive, continuous emissions, off-gassing, from materials such as furniture, construction products, and household goods, rather than direct links to occupant behaviours. These emissions were not associated with short-term activity peaks but could be influenced by environmental conditions such as temperature and ventilation.

Figure 1. Twenty-four-hour indoor concentration profiles in selected at-risk homes (µg/m³). *Panel A) PM$_{2.5}$ exposure. Panel B) Formaldehyde exposure. The exposure was recorded at 10-min intervals with MICA-IBIOT LCS; screenshots exported from the myInbiot monitoring platform.*

As shown in **Figure 2,** the distributions of IAQ risk categories for CO_2, PM$_{2.5}$ and formaldehyde were similar in patients that suffered severe pulmonary exacerbations requiring hospitalisation during the previous year of IAQ assessment and those without events. Only, PM$_{2.5}$ showed a modest, non-statistically significant, shift toward higher PM$_{2.5,}$ exposure among hospitalised patients. Similar distributions were observed when stratifying by all-cause emergency department visits.

Figure 2. IAQ risk categories by pollutant and hospitalisation status. *Stacked bars show the proportion of dwellings in Low, Moderate, and Unhealthy GO-AQS categories for each pollutant (CO_2, formaldehyde, PM_{25}), stratified by patients with no admissions (n=128) versus those hospitalised for severe pulmonary exacerbations (n=50). Percentages within bars indicate the share of homes per risk category in each subgroup.*

Discussion

Main findings

This research generated three main findings.

First, LCS demonstrated clear operational utility for patient-centred environmental monitoring. In field deployment, the sensors exhibited stable, approximately linear responses over the observed ranges and consistently captured relative changes and temporal patterns, enabling reliable characterisation of household exposure profiles.

Second, poor household IAQ is a prevalent phenomenon and predominantly $PM_{2.5}$ driven. More than half of the monitored homes exhibited moderate or unhealthy risk levels for at least one pollutant, with $PM_{2.5}$ accounting for most at-risk classifications and for a larger share of time accrued in higher risk bands.

Third, associations between impaired IAQ and the occurrence of severe pulmonary exacerbations were inconclusive at this stage. IAQ risk distributions did not differ materially between patients with and without hospitalisation for severe pulmonary exacerbations. Comparable patterns were observed for all-cause emergency department visits.

Taken together, these observations support incorporating household IAQ monitoring with LCS as a complementary element of integrated care for selected patients with COPD and severe asthma. On this basis, we summarise below the principal lessons learned and pragmatic recommendations for clinical deployment.

Lessons learned and practical implications for clinical use

Household IAQ monitoring with LCS – In this real-world deployment, LCS provided sufficiently stable, approximately linear responses in the working ranges for $PM_{2.5}$ and formaldehyde, enabling reliable detection of relative changes and characterization of home-level exposure profiles. These observations are consistent with independent evaluations of LCS performance[20–22]. By contrast, total VOC signals were prone to overestimation and cross-interference and were therefore unsuitable for absolute quantification, though they retained qualitative value for flagging high-emission events. CO_2 should be interpreted primarily as a ventilation/occupancy surrogate rather than a pollutant, aiding the contextualization of IAQ episodes.

Moreover, given the time-demandant maintenance needs and synchronization requirements of the IAQ monitors, in addition to the relative stability of household exposure patterns once sources are identified, indefinite monitoring is rarely cost-effective. We therefore recommend time-limited IAQ campaigns to characterise exposures in selected high-risk patients (e.g., difficult-to-control COPD/asthma) and to assess the efficacy of environmental interventions or behavioural changes (e.g., smoking cessation).

Clinical decision-making would be strengthened by multi-pollutant sensing that includes oxidant gases and improved VOC specificity. Oxidant gases are associated with respiratory morbidity and can amplify PM-related oxidative stress and airway inflammation when present together, potentially increasing the risk of exacerbations[47]; a multi-pollutant view is therefore biologically and clinically coherent. Incorporating validated NO_2/O_3 sensing could improve early detection of hazardous indoor conditions, trigger timely prevention of acute exacerbations.

PM2.5 and formaldehyde exposure - We observed a strong association between indoor $PM_{2.5}$ levels and active smoking, reinforcing tobacco use as a principal driver of household particle pollution. Nevertheless, elevated $PM_{2.5}$ in non-smoker dwellings indicates additional relevant sources, most notably cooking emissions, combustion appliances, and cleaning/resuspension, underscoring the need for context-specific mitigation. These results emphasise the biological relevance of PM exposure beyond tobacco smoke and support tailored recommendations to reduce particulate burden. From an intervention point-of-view, patient self-management is central: smoking cessation, effective kitchen extraction, timely ventilation, avoiding incense/candles, minimising dust-raising cleaning methods, might be enough to attenuate PM peaks.

In contrast, formaldehyde reflects ubiquitous off-gassing from furnishings and building materials and is therefore best addressed through source reduction/substitution, sustained ventilation, and thermal management. Gas-phase removal is feasible only with sorbent media (e.g., activated carbon/chemisorption cartridges); given structural emission sources and the relatively small number of dwellings with unhealthy formaldehyde levels in our sample, intensive remediation should be reserved for selected severe cases.

The role of IAQ in the prevention of acute events – Despite robust epidemiological evidence linking air pollution to respiratory morbidity and exacerbations[15,16], our retrospective analysis did not detect statistically significant associations between household IAQ categories and unplanned hospitalisations for severe pulmonary exacerbations. Several factors likely explain the absence of detectable signals at this interim stage. First, our outcome focused on hospitalised exacerbations, excluding the broader spectrum of milder events managed in the community. Second, severe events in complex patients arise from the interplay of multiple risk domains[48,49], such as multimorbidity, lung function, and the history of previous events as observed in the study cohort, which can attenuate marginal associations from environmental exposures in modest samples. Third, due to the maturity of the IAQ sensors, our approach only considered CO_2, formaldehyde and $PM_{2.5}$. In this regard, biological agents (respiratory viruses and bacteria) are primary triggers of exacerbations, while co-exposure to $PM_{2.5}$ and oxidant gases might amplify airway inflammation and increase exacerbation risk. Future studies that incorporate multi-pollutant monitoring alongside bioaerosol control to clarify exposure–response pathways and guide prevention of acute events.

Digital infrastructure - The architecture supporting the intervention reported in [28], built on a cloud-based adaptive case management platform[50], offers scalability and operational flexibility, enabling potential adoption across diverse clinical contexts. This is especially relevant given the transition towards digitally supported, value-based care models in chronic disease management. Importantly, IAQ monitoring via LCS is not a standalone solution but a complementary tool within a broader, holistic management strategy. Its potential lies in identifying environmental triggers, guiding patient education, and informing clinical decision-making in difficult-to-manage patients.

Future perspectives

To overcome some of the limitations of this study, during the remaining project period through March 2026, the study will complete prospective data collection and broaden outcome assessment beyond hospitalisations to include mild/moderate exacerbations managed in the community according to the published protocol[28]. This will allow analyses over a complete calendar year, enabling assessment of seasonality in IAQ and its temporal relationships with clinical events. In parallel, a pragmatic evaluation of in-home filtration in at-risk dwellings, HEPA for particulate matter and activated carbon for gas-phase pollutants such as formaldehyde, must be conducted to assess the efficacy of environmental interventions in the most severely polluted dwellings.

Conclusions

In conclusion, our findings support the feasibility and potential value of remote IAQ monitoring with LCS in respiratory medicine. While not a substitute for high-precision equipment, LCS offers a scalable, affordable, and patient-friendly solution for continuous environmental assessment. Their integration into co-designed, community-based interventions may improve understanding, prevention, and management of exacerbations in high-risk patients. The ongoing follow-up will provide critical evidence to inform future recommendations and define the clinical utility of IAQ monitoring as part of holistic value-based care strategies for chronic respiratory diseases. Such approaches could represent an important step toward addressing the environmental determinants of respiratory health and reducing the substantial burden of preventable hospitalizations.

Abbreviations:

ACM: Adaptive Case Management; **AIQ:** Indoor Air Quality; **AISBE:** Integrated Health Care District of Barcelona-Esquerra; **AMG:** Adjusted Morbidity Groups; **ATS:** American Thoracic Society; **CAT:** COPD Assessment Test; **CHSS:** Catalan Health Surveillance System; **COPD:** Chronic Obstructive Pulmonary Disease; **FEV1:** Forced Expiratory Volume in 1 second; **FVC:** Forced Vital Capacity; **GO AQS:** Global Open Air Quality Standards; **HCB:** Hospital Clínic de Barcelona; **HR:** Heart Rate; **HRV:** Heart Rate Variability; **IAQ:** Indoor Air Quality; **ICD-10-CM:** International Classification of Diseases, 10th Revision, Clinical Modification; **IDEAL Cluster:** Indoor Air Quality and Health Research & Innovation Program; **LCS:** Low-Cost Sensors; **mMRC:** Modified Medical Research Council Dyspnea Scale; **NOx:** Nitrogen Oxides; **PM:** Particulate Matter; **PM1:** Particulate Matter ≤1μm; **PM2.5:** Particulate Matter ≤2.5μm; **PM10:** Particulate Matter ≤10μm; **SD:** Standard Deviation; **VOCs:** Volatile Organic Compounds.

Data Availability:

The datasets generated and/or analysed during the current study contain sensitive patient information and will not be openly distributed. However, anonymized data may be made available upon reasonable request to the corresponding author, subject to institutional data sharing agreements and ethical approval.

Authors' Contributions:

RGC, JJR, IC, JF, and EA conceived and supervised the study. RGC developed the statistical analysis plan, performed the data analysis, and created the figures. AGL was responsible for patient recruitment, cohort follow-up, and data collection as part of the study's nursing role. NS, NSR, MS, JB, ASA, and EA represented the medical teams from both hospital and primary care, contributing to the study's clinical aspects. MF provided expertise as a representative of the monitoring technology providers. AA, JF, and AR contributed their expertise in IAQ and performed the laboratory validation of the environmental sensors. RF served as an advisor on Oscillometry procedures. EV and JPJ facilitated access to regional health data and provided statistical support. RGC, AGL, JR, IC, and EA led the manuscript drafting. All authors contributed to the writing, reviewed the manuscript and approved the final version.

Acknowledgements:

The K-HEALTHinAIR project funded this study, Grant Agreement nº 101057693, under a European Union's Call on Environment and Health (HORIZON-HLTH-2021-ENVHLTH-02).

This research was also supported by the Catalan Government and the Catalan Department of Research and Universities under contract 2021 SGR 00326.

Disclaimer: Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency as granting authority. Neither the European Union nor the granting authority can be held responsible.

Competing Interests:

IC and JR hold shares in Health Circuit SL. JR contributes to the Astra-Zeneca Global Oscillometry Advisory Board. MF is the Chief Scientific Officer of inBioT, the manufacturer of the MICA sensors utilized in this study.

All other authors declare no conflicts of interest.

References:

1. FULLER G ET AL. *Impacts of Air Pollution across the Life Course – Evidence Highlight Note.*; 2023. Accessed February 12, 2025. https://www.london.gov.uk/sites/default/files/2023-04/Imperial College London Projects - impacts of air pollution across the life course – evidence highlight note.pdf

2. CHEN J ET AL. Long-Term Exposure to Fine Particle Elemental Components and Natural and Cause-Specific Mortality-a Pooled Analysis of Eight European Cohorts within the ELAPSE Project. *Environ Health Perspect*. 2021;129(4):47009. doi:10.1289/EHP8368

3. TURNER MC ET AL. Clean air in Europe for all! Taking stock of the proposed revision to the ambient air quality directives: a joint ERS, HEI and ISEE workshop report. *Eur Respir J*. 2023;62(4). doi:10.1183/13993003.01380-2023

4. RAJU S ET AL. Indoor Air Pollution and Impaired Cardiac Autonomic Function in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2023;207(6):721-730. doi:10.1164/rccm.202203-0523OC

5. Raju S et al. Indoor Air Pollution, CT Airway-to-Lung Ratio and Lung Function Decline: Analyses from SPIROMICS AIR. *Am J Respir Crit Care Med*. Published online February 2025. doi:10.1164/rccm.202404-0834RL

6. Brems JH et al. An Issue of Caliber: The Airway Tree and Air Pollution Susceptibility. *Am J Respir Crit Care Med*. 2024;209(11):1294-1295. doi:10.1164/rccm.202401-0146ED

7. Orellano P et al. Short-term exposure to particulate matter (PM(10) and PM(2.5)), nitrogen dioxide (NO(2)), and ozone (O(3)) and all-cause and cause-specific mortality: Systematic review and meta-analysis. *Environ Int*. 2020;142:105876. doi:10.1016/j.envint.2020.105876

8. Kang DS et al. Network-based integrated analysis for toxic effects of high-concentration formaldehyde inhalation exposure through the toxicogenomic approach. *Sci Rep*. 2022;12(1):5645. doi:10.1038/s41598-022-09673-0

9. Lam J et al. Exposure to formaldehyde and asthma outcomes: A systematic review, meta-analysis, and economic assessment. *PLoS One*. 2021;16(3):e0248258. doi:10.1371/journal.pone.0248258

10. Soni V et al. Effects of VOCs on Human Health. In: Sharma N, Agarwal AK, Eastwood P, Gupta T, Singh AP, eds. *Air Pollution and Control*. Springer Singapore; 2018:119-142. doi:10.1007/978-981-10-7185-0_8

11. Mortality, morbidity and welfare cost from exposure to environment-related risks - OECD Data Explorer. Accessed January 20, 2025. https://data-explorer.oecd.org/vis?lc=en&fs[0]=Topic%2C0%7CEnvironment and climate change%23ENV%23&pg=20&fc=Topic&bp=true&snb=47&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_EXP_MORSC%40DF_EXP_MORSC&df[ag]=OECD.ENV.EPI&df[vs]=1.0&dq=.A.DALY.10P3HB.PM_2_5_OUT._

12. Breathing Clean Air - World Health Organization (WHO). Published 2022. Accessed January 20, 2025. https://www.who.int/tools/your-life-your-health/other-health-topics/health-and-the-environment/breathing-clean-air

13. Summary of the Clean Air Act - U.S. Environmental Protection Agency (US EPA). Accessed January 20, 2025. https://www.epa.gov/laws-regulations/summary-clean-air-act

14. Harm to human health from air pollution in Europe: burden of disease 2023 — European Environment Agency (EEA). Accessed January 20, 2025. https://www.eea.europa.eu/publications/harm-to-human-health-from-air-pollution

15. Manisalidis I et al. Environmental and Health Impacts of Air Pollution: A Review. *Front Public Health*. 2020;8. doi:10.3389/fpubh.2020.00014

16. Martins C et al. Sources, levels, and determinants of indoor air pollutants in Europe: A systematic review. *Science of The Total Environment*. 2025;964:178574. doi:https://doi.org/10.1016/j.scitotenv.2025.178574

17. Lai PS et al. Household Air Pollution Interventions to Improve Health in Low- and Middle-Income Countries: An Official American Thoracic Society Research Statement. *Am J Respir Crit Care Med*. 2024;209(8):909-927. doi:10.1164/rccm.202402-0398ST

18. NASSIKAS NJ ET AL. Indoor Air Sources of Outdoor Air Pollution: Health Consequences, Policy, and Recommendations: An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2024;21(3):365-376. doi:10.1513/AnnalsATS.202312-1067ST

19. IDEAL CLUSTER - INDOOR AIR QUALITY AND HEALTH - THE EUROPEAN CLUSTER TO IMPROVE AND SAFEGUARD HEALTH AND WELL-BEING OF CITIZENS IN INDOOR ENVIRONMENTS. Accessed January 20, 2025. https://www.idealcluster.eu/

20. RÓDENAS GARCÍA M ET AL. Review of low-cost sensors for indoor air quality: Features and applications. *Appl Spectrosc Rev*. 2022;57(9-10):747-779. doi:10.1080/05704928.2022.2085734

21. AGUADO A ET AL. Verification and Usability of Indoor Air Quality Monitoring Tools in the Framework of Health-Related Studies. *Air*. 2025;3(1). doi:10.3390/air3010003

22. KARAGULIAN F ET AL. Review of the Performance of Low-Cost Sensors for Air Quality Monitoring. *Atmosphere (Basel)*. 2019;10(9). doi:10.3390/atmos10090506

23. HANSEL NN ET AL. Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and Chronic Obstructive Pulmonary Disease Health Results of the CLEAN AIR Study. *Am J Respir Crit Care Med*. 2022;205(4):421-430. doi:10.1164/RCCM.202103-0604OC/SUPPL_FILE/DISCLOSURES.PDF

24. BALMES JR ET AL. Tiny Particles, Big Health Impacts. *Am J Respir Crit Care Med*. 2024;210(11):1291-1292. doi:10.1164/rccm.202407-1476ED

25. HANSEL NN ET AL. In-home air pollution is linked to respiratory morbidity in former smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2013;187(10):1085-1090. doi:10.1164/rccm.201211-1987OC

26. SOLER-CATALUÑA JJ ET AL. Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study. *Int J Chron Obstruct Pulmon Dis*. 2023;18:1103-1114. doi:10.2147/COPD.S406007

27. VOGELMEIER CF ET AL. COPD Exacerbation History and Impact on Future Exacerbations - 8-Year Retrospective Observational Database Cohort Study from Germany. *Int J Chron Obstruct Pulmon Dis*. 2021;16:2407-2417. doi:10.2147/COPD.S322036

28. GÓMEZ-LÓPEZ A ET AL. Protocol for the enhanced management of multimorbid patients with COPD and severe asthma: role of indoor air quality. *BMJ Open Respir Res*. 2025;12(1). doi:10.1136/bmjresp-2024-002589

29. K-HEALTH IN AIR (2022 - 2026). Knowledge for Improving Indoor Air Quality and Health (K-Health in Air). Published 2022. https://k-healthinair.eu/

30. FONT D ET AL. Integrated Health Care Barcelona Esquerra (Ais-Be): A Global View of Organisational Development , Re-Engineering of Processes and Improvement of the Information Systems . The Role of the Tertiary University Hospital in the Transformation. 2016;16(2):1-10.

31. FARRÉ N ET AL. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. *Eur J Heart Fail*. 2016;18(9):1132-1140. doi:10.1002/ejhf.549

32. ICD - ICD-10-CM - INTERNATIONAL CLASSIFICATION OF DISEASES, TENTH REVISION, CLINICAL MODIFICATION. Accessed July 21, 2021. https://www.cdc.gov/nchs/icd/icd10cm.htm

33. VELA E ET AL. Population-based analysis of patients with COPD in Catalonia: a cohort study with implications for clinical management. *BMJ Open*. 2018;8(3):e017283. doi:10.1136/BMJOPEN-2017-017283

34. MONTERDE D ET AL. Adjusted morbidity groups: A new multiple morbidity measurement of use in Primary Care. *Aten Primaria*. 2016;48(10):674-682. doi:10.1016/J.APRIM.2016.06.003

35. CEREZO-CEREZO J ET AL. GOOD PRACTICE BRIEF - Population stratification: A fundamental instrument used for population health management in Spain. Published 2018. Accessed March 2, 2022. https://iris.who.int/bitstream/handle/10665/345586/WHO-EURO-2018-3032-42790-59709-eng.pdf?sequence=3

36. VENKATESAN P. 2023 GINA report for asthma. *Lancet Respir Med*. 2023;11(7):589. doi:10.1016/S2213-2600(23)00230-8

37. PLAZA MORAL V ET AL. GEMA 5.3. Spanish Guideline on the Management of Asthma. *Open respiratory archives*. 2023;5(4):100277. doi:10.1016/j.opresp.2023.100277

38. CELLI BR ET AL. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposal. *Am J Respir Crit Care Med*. 2021;204(11):1251-1258. doi:10.1164/RCCM.202108-1819PP/SUPPL_FILE/DISCLOSURES.PDF

39. AGUSTÍ A ET AL. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Am J Respir Crit Care Med*. 2023;207(7):819-837. doi:10.1164/rccm.202301-0106PP

40. POLVERINO E ET AL. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J*. 2017;50(3). doi:10.1183/13993003.00629-2017

41. VANDENBROUCKE JP ET AL. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med*. 2007;147(8):W163-94. doi:10.7326/0003-4819-147-8-200710160-00010-w1

42. MICA - MONITOR INTELIGENTE DE CALIDAD DE AIRE INTERIOR. Accessed August 14, 2025. https://www.inbiot.es/es/productos/dispositivos-mica/mica

43. GO AQS WHITE PAPER V0.90 – UPDATE – GO AQS. Accessed August 14, 2025. https://goaqs.org/2025/07/23/go-aqs-white-paper-v0-90-update/

44. WORLD HEALTH ORGANIZATION (WHO). *WHO Global Air Quality Guidelines: Particulate Matter (PM2.5 and PM10), Ozone, Nitrogen Dioxide, Sulfur Dioxide and Carbon Monoxide.*; 2021.

45. WORLD HEALTH ORGANIZATION (WHO). *WHO Guidelines for Indoor Air Quality: Selected Pollutants.*; 2010. Accessed March 17, 2025. https://www.euro.who.int/__data/assets/pdf_file/0009/128169/e94535.pdf

46. R CORE TEAM. R: A language and environment for statistical computing. Published online 2021.

47. RUSSO RC ET AL. Ozone-induced lung injury and inflammation: Pathways and therapeutic targets for pulmonary diseases caused by air pollutants. *Environ Int*. 2025;198:109391. doi:https://doi.org/10.1016/j.envint.2025.109391

48. HURST JR ET AL. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. *New England Journal of Medicine*. 2010;363(12):1128-1138. doi:10.1056/NEJMoa0909883

49. HURST JR ET AL. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. *Respiratory Research 2022 23:1*. 2022;23(1):1-23. doi:10.1186/S12931-022-02123-5

50. HERRANZ C ET AL. A Practice-Proven Adaptive Case Management Approach for Innovative Health Care Services (Health Circuit): Cluster Randomized Clinical Pilot and Descriptive Observational Study. *J Med Internet Res*. 2023;25:e47672. doi:10.2196/47672

A PM 2.5 concentration over 24h in a selected home

B Formaldehyde concentration over 24h in a selected home

A.

Retrospective healthcare surveillance

1 Apr 2024

1 Apr 2025 **IAQ monitoring** 31 May 2025

COPD
SEVERE ASTHMA

★ Pulmonary exacerbations requiring unplanned hospital admissions (Principal Dx: ICD-10 J00–J99)

★ All-cause emergency room visits

B.

	GO-AQS Low exposure	GO-AQS Moderate exposure	GO-AQS Unhealty exposure
CO2	400-850 ppm	851-1400 ppm	1401-5000 ppm
H2CO	0-50 µg/m3	51-120 µg/m3	121-500 µg/m3
PM2.5	0-8 µg/m3	9-35 µg/m3	36-400 µg/m3